Skip to main content
. 2022 Mar 4;77:103906. doi: 10.1016/j.ebiom.2022.103906

Figure 3.

Fig. 3

On the top: major resistance mutations on HIV-RNA at ibalizumab start (according to Stanford HIVDb version 9.0, last updated on 2021-02-22), from the right to the left on NRTI, NNRTI, PI, InSTI. Graphic: HIV-RNA (orange line) and CD4+ T-cell count (blue line) trend represented by all the available values since the first years after HIV-1 infection diagnosis to ibalizumab start (blue arrow on the right), and then monthly until data freezing. Antiretroviral dosages: enfuvirtide 90 mg iv twice daily (td), darunavir/ritonavir 600/100 mg td, maraviroc 300 mg td, dolutegravir 50 mg td, fostemsavir 600 mg td, ibalizumab administered iv at a 2000 mg loading dose followed by 800 mg every 14 days.